BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 8388583)

  • 1. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor.
    Bara L; Bloch MF; Zitoun D; Samama M; Collignon F; Frydman A; Uzan A; Bouthier J
    Thromb Res; 1993 Mar; 69(5):443-52. PubMed ID: 8388583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma.
    Bendetowicz AV; Bara L; Samama MM
    Thromb Res; 1990 Jun; 58(5):445-54. PubMed ID: 2164262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma.
    Gerotziafas GT; Bara L; Bloch MF; Makris PE; Samama MM
    Blood Coagul Fibrinolysis; 1998 Oct; 9(7):571-80. PubMed ID: 9863704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).
    Samama MM; Bara L; Gerotziafas GT
    Haemostasis; 1994; 24(2):105-17. PubMed ID: 7959358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
    Eriksson BI; Söderberg K; Widlund L; Wandeli B; Tengborn L; Risberg B
    Thromb Haemost; 1995 Mar; 73(3):398-401. PubMed ID: 7667822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
    Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
    Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; Dunwiddie CT; Perrone MH
    Arterioscler Thromb Vasc Biol; 1998 Jun; 18(6):908-14. PubMed ID: 9633930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
    Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
    Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit.
    Briant L; Caranobe C; Saivin S; Sié P; Bayrou B; Houin G; Boneu B
    Thromb Haemost; 1989 Jun; 61(3):348-53. PubMed ID: 2552603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
    Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
    Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins.
    Bendz B; Hansen JB; Andersen TO; Ostergaard P; Sandset PM
    Br J Haematol; 1999 Dec; 107(4):756-62. PubMed ID: 10606880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4).
    Padilla A; Gray E; Pepper DS; Barrowcliffe TW
    Br J Haematol; 1992 Oct; 82(2):406-13. PubMed ID: 1329921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers.
    Antonijoan RM; Rico S; Martínez-González J; Borrell M; Valcarcel D; Fontcuberta J; Barbanoj MJ
    Int J Clin Pharmacol Ther; 2009 Dec; 47(12):726-32. PubMed ID: 19954711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of the pharmacokinetic profiles of two LMWHs--bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)--administered subcutaneously to healthy male volunteers.
    Depasse F; González de Suso MJ; Lagoutte I; Fontcuberta J; Borrell M; Samama MM
    Thromb Res; 2003 Jan; 109(2-3):109-17. PubMed ID: 12706639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans.
    Kaiser B; Hoppensteadt DA; Jeske W; Wun TC; Fareed J
    Thromb Res; 1994 Sep; 75(6):609-16. PubMed ID: 7831680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of exosite binding modulators in the inhibition of Fxa by TFPI.
    Peraramelli S; Thomassen S; Heinzmann A; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M; Rosing J
    Thromb Haemost; 2016 Mar; 115(3):580-90. PubMed ID: 26607136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of different anticoagulant agents on fibrinopeptide a generation.
    Tobu M; Iqbal O; Messmore HL; Ma Q; Hoppensteadt DA; Fareed J
    Clin Appl Thromb Hemost; 2003 Oct; 9(4):273-92. PubMed ID: 14653437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
    Spencer FA; Ball SP; Zhang Q; Liu L; Benoit S; Becker RC
    J Thromb Thrombolysis; 2000 Apr; 9(3):223-8. PubMed ID: 10728020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin.
    Harenberg J; Malsch R; Angelescu M; Lange C; Michaelis HC; Wolf H; Heene DL
    Blood Coagul Fibrinolysis; 1996 Jun; 7(4):477-83. PubMed ID: 8840001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.